Your browser is no longer supported. Please, upgrade your browser.
Prothena Corporation plc
Index- P/E- EPS (ttm)-2.78 Insider Own0.05% Shs Outstand39.92M Perf Week9.09%
Market Cap1.13B Forward P/E- EPS next Y-3.64 Insider Trans- Shs Float20.72M Perf Month0.24%
Income-111.10M PEG- EPS next Q-0.54 Inst Own80.90% Short Float9.08% Perf Quarter72.57%
Sales0.90M P/S1252.44 EPS this Y-43.00% Inst Trans-3.74% Short Ratio3.73 Perf Half Y121.28%
Book/sh4.61 P/B5.39 EPS next Y-175.80% ROA-30.30% Target Price31.14 Perf Year116.84%
Cash/sh6.51 P/C3.82 EPS next 5Y-8.40% ROE-50.30% 52W Range9.25 - 28.66 Perf YTD106.91%
Dividend- P/FCF- EPS past 5Y-0.90% ROI-61.10% 52W High-16.50% Beta1.54
Dividend %- Quick Ratio11.60 Sales past 5Y-11.90% Gross Margin- 52W Low158.70% ATR1.86
Employees66 Current Ratio11.60 Sales Q/Q33.30% Oper. Margin- RSI (14)51.12 Volatility7.45% 8.74%
OptionableYes Debt/Eq0.00 EPS Q/Q-42.40% Profit Margin- Rel Volume0.31 Prev Close24.85
ShortableYes LT Debt/Eq0.00 EarningsFeb 11 BMO Payout- Avg Volume504.77K Price23.93
Recom1.90 SMA20-1.67% SMA506.42% SMA20062.90% Volume100,330 Change-3.70%
Feb-26-21Upgrade RBC Capital Mkts Sector Perform → Outperform $14 → $28
Feb-12-21Upgrade Jefferies Hold → Buy $15 → $30
Feb-02-21Upgrade BTIG Research Neutral → Buy $29
Dec-07-20Initiated H.C. Wainwright Buy $22
Jul-09-20Upgrade Oppenheimer Perform → Outperform $16
Nov-19-19Upgrade Evercore ISI In-line → Outperform $14
May-21-18Downgrade Barclays Equal Weight → Underweight $14 → $12
Apr-23-18Downgrade Jefferies Buy → Hold
Apr-05-18Reiterated Barclays Overweight $70 → $50
Nov-20-17Downgrade Wedbush Outperform → Neutral $75 → $55
Sep-29-17Reiterated BTIG Research Buy $80 → $77
Sep-15-17Initiated RBC Capital Mkts Outperform $87
Aug-17-17Initiated Evercore ISI Outperform $83
Jul-11-17Initiated Jefferies Buy
Apr-12-17Initiated Piper Jaffray Overweight $69
Apr-12-17Initiated Cantor Fitzgerald Overweight $86
Mar-02-17Initiated Instinet Buy $87
Dec-21-16Initiated SunTrust Buy $75
Nov-03-16Initiated Deutsche Bank Buy $73
Aug-04-16Reiterated Barclays Overweight $60 → $70
Apr-18-21 03:05PM  
Apr-15-21 04:05PM  
Apr-07-21 04:05PM  
Apr-05-21 04:05PM  
Mar-29-21 08:22AM  
Mar-25-21 11:37AM  
Mar-24-21 08:00AM  
Mar-23-21 04:29PM  
Mar-13-21 10:30AM  
Mar-11-21 08:19AM  
Mar-08-21 04:05PM  
Feb-24-21 04:05PM  
Feb-12-21 05:11PM  
Feb-11-21 09:19AM  
Feb-05-21 04:05PM  
Feb-04-21 04:05PM  
Feb-03-21 12:30PM  
Feb-01-21 04:15PM  
Dec-09-20 08:00AM  
Dec-04-20 04:05PM  
Nov-27-20 12:25AM  
Nov-16-20 02:56AM  
Nov-05-20 11:13AM  
Nov-04-20 06:35PM  
Oct-28-20 04:05PM  
Oct-21-20 10:48AM  
Oct-20-20 04:05PM  
Oct-02-20 04:05PM  
Sep-29-20 02:35PM  
Sep-15-20 08:30AM  
Sep-11-20 08:30AM  
Sep-08-20 04:05PM  
Sep-05-20 11:31AM  
Sep-03-20 04:05PM  
Sep-02-20 04:05PM  
Aug-06-20 08:10PM  
Aug-05-20 04:05PM  
Aug-03-20 12:09PM  
Jul-30-20 04:05PM  
Jul-28-20 12:33PM  
Jul-10-20 08:34AM  
Jun-19-20 12:47PM  
May-27-20 04:05PM  
May-18-20 07:26AM  
May-06-20 07:45PM  
Apr-29-20 04:05PM  
Apr-28-20 12:33PM  
Apr-24-20 04:30PM  
Apr-22-20 09:15AM  
Apr-21-20 10:20AM  
Apr-03-20 04:05PM  
Mar-31-20 04:05PM  
Mar-13-20 11:30AM  
Mar-03-20 04:05PM  
Feb-17-20 06:31PM  
Feb-13-20 10:45AM  
Feb-12-20 05:35PM  
Feb-05-20 04:05PM  
Jan-20-20 11:21AM  
Dec-30-19 08:35AM  
Dec-11-19 03:47PM  
Dec-05-19 04:05PM  
Nov-19-19 11:03AM  
Nov-06-19 03:14PM  
Nov-05-19 06:55PM  
Oct-29-19 04:05PM  
Oct-15-19 01:49AM  
Oct-07-19 09:00AM  
Sep-20-19 01:04PM  
Sep-11-19 01:39PM  
Sep-05-19 09:31AM  
Aug-06-19 07:25PM  
Jul-30-19 04:05PM  
Jul-05-19 04:39PM  
Jul-03-19 03:26PM  
Jul-01-19 04:05PM  
Jun-06-19 09:31AM  
May-30-19 04:05PM  
May-11-19 01:28PM  
May-08-19 08:51AM  
May-07-19 06:55PM  
Apr-30-19 04:05PM  
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other tauopathies; A, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegenerative diseases. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EcoR1 Capital, LLC10% OwnerMar 24Buy20.75875,00018,156,25011,034,280Mar 25 11:14 AM
EcoR1 Capital, LLC10% OwnerFeb 24Buy22.0210,800237,86710,159,280Feb 25 06:00 PM
EcoR1 Capital, LLC10% OwnerFeb 23Buy21.0544,400934,51810,148,480Feb 25 06:00 PM
Zago Wagner M.Chief Scientific OfficerFeb 18Option Exercise6.417,54048,3317,540Feb 19 06:39 PM
EcoR1 Capital, LLC10% OwnerFeb 18Buy3.6844,100162,10310,104,080Feb 22 04:24 PM
Zago Wagner M.Chief Scientific OfficerFeb 18Sale25.507,540192,2700Feb 19 06:39 PM
EcoR1 Capital, LLC10% OwnerFeb 17Buy23.46198,8404,665,54210,059,980Feb 17 07:14 PM
EcoR1 Capital, LLC10% OwnerFeb 16Buy22.7889,2002,031,9679,861,140Feb 17 07:14 PM
Zago Wagner M.Chief Scientific OfficerFeb 12Option Exercise11.4826,310302,14718,750Feb 17 06:47 PM
EcoR1 Capital, LLC10% OwnerFeb 12Buy20.16345,3006,959,7619,771,940Feb 17 07:14 PM
Zago Wagner M.Chief Scientific OfficerFeb 12Sale19.1626,310504,0570Feb 17 06:47 PM
Kinney Gene G.President and CEOAug 17Option Exercise6.4110,00064,10012,793Aug 19 04:31 PM